
Opinion|Videos|February 7, 2025
Safety Profile of New Therapies
Panelists discuss how both medications demonstrate favorable safety profiles in clinical trials, with aflibercept 8 mg benefiting from extensive 2-mg safety data, while acknowledging the need to monitor intraocular pressure due to increased injection volume, particularly in at-risk patients.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Based on the clinical trial data, how do you view the safety profiles of faricimab and aflibercept 8 mg?
- Does the long-term safety profile of aflibercept 2 mg increase your confidence in the safety of aflibercept 8 mg?
- Does the increased volume of aflibercept 8 mg raise concerns about the potential for elevated intraocular pressure? How do you evaluate and address this in clinical practice?
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Q&A: Evolving approaches to geographic atrophy management
2
Exploring Emerging Therapies in the Retinal Vascular Disease Pipeline
3
Rates of retinal layer thinning predict visual field progression in glaucoma
4
First patient treated in dose-expansion portion of SpliceBio's phase 1/2 ASTRA clinical trial
5















































